LBF20203PG01

LipidBank Top (トップ)

Fatty acid (脂肪酸)

Glycerolipid (グリセロ脂質)

Sphingolipid (スフィンゴ脂質)

Journals (雑誌一覧)

How to edit (ページの書き方)

Upper classes: LB LBF

IDs and Links
LipidBank	XPR1706
LipidMaps	LMFA03010143
CAS
KEGG	{{{KEGG}}}
KNApSAcK	{{{KNApSAcK}}}
mol	LBF20203PG01

Δ17-Prostaglandin E1
Structural Information
Systematic Name	9-oxo-11α,15S-dihydroxy-prosta-13E,17Z-dien-1-oic acid
Common Name	Δ17-Prostaglandin E1 9-oxo-11α,15S-dihydroxy-prosta-13E,17Z-dien-1-oic acid
Symbol
Formula	C20H32O5
Exact Mass	352.224974134
Average Mass	352.46508
SMILES	C(=CC[C@@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC
Physicochemical Information
Melting Point
Boiling Point
Density
Optical Rotation
Refractive Index
Solubility
Source	D17-PGE1 is produced by the cyclooxigenase metabolism of w-3 arachidonic acid.
Chemical Synthesis
Metabolism
Biological Activity	D17-PGE1 is about half as potent as PGE1 as an inhibitor of ADP-induced aggregation of rabbbit PRP. Kobzar_G et al. In humanPRP, D17-PGE1 is a more potent antiplatelet agonist than PGE1.
Genetic Information
Note
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms

Reported Metabolites, References
Biospecies ID Compound Name Reference Comment n.a. LBF20203PG01 See above. Kobzar_G et al. 1993